NCT02660827

Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 151 (actual)
• Sponsor: Medtronic MiniMed, Inc. · Industry
• Sex: All
• Age: 2 Years – 13 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm is safe as part of the overall system, and to assess the PLGM feature in 7-13 years old subjects.

Detailed description

The study will proceed as follows: Run-in Period - General: A total of up to 200 subjects (age 2-13) will be enrolled at up to 15 investigational centers (14 in the US, 1 EMEA) in order to reach 120 subjects who will complete the HCL study. Study Period - At Home: Following the two week run-in period using the Study Pump (670G), all subjects (age 2-13) will participate in a 3-month study period. Study Period - Hotel Study Subjects (age 7-13) will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. Subjects 2-6 years of age are not required to participate in a hotel study. Instead, they will participate in an out-of-home study for 5 consecutive days, 4-6 hours per day. Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of up to 3 years . If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DEVICE	Insulin Pump	Closed Loop Algorithm

Timeline

• Start date: 2016-04-18
• Primary completion: 2018-11-28
• Completion: 2021-02-01
• First posted: 2016-01-21
• Last updated: 2022-01-26
• Results posted: 2019-01-11

Locations

11 sites across 2 countries: United States, Israel